(NASDAQ: CYTK) Cytokinetics's forecast annual revenue growth rate of 100% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.42%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.02%.
Cytokinetics's revenue in 2026 is $105,815,000.On average, 24 Wall Street analysts forecast CYTK's revenue for 2026 to be $14,542,433,872, with the lowest CYTK revenue forecast at $10,991,999,494, and the highest CYTK revenue forecast at $23,825,103,221. On average, 23 Wall Street analysts forecast CYTK's revenue for 2027 to be $50,706,270,238, with the lowest CYTK revenue forecast at $38,437,219,329, and the highest CYTK revenue forecast at $71,145,563,364.
In 2028, CYTK is forecast to generate $109,851,557,033 in revenue, with the lowest revenue forecast at $85,273,636,795 and the highest revenue forecast at $141,728,691,535.